Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) reported financial results for the fourth quarter and full year ended December 31, 2011. Net sales for the fourth quarter were $75.5 million, reflecting continued physician acceptance of H.P. Acthar® Gel (Acthar) for treating serious, difficult-to-treat medical conditions. Net sales in the fourth quarter 2010 were $29.3 million. GAAP net income for the fourth quarter of 2011 was $31.6 million or $0.48 per diluted common share. GAAP net income for the fourth quarter of 2010 was $6.4 million, or $0.10 per diluted common share. Non-GAAP net income (which excludes non-cash share-based compensation expense, depreciation and amortization expense, tax adjustments and a goodwill impairment charge) for the quarter ended December 31, 2011 was $31.6 million or $0.47 per diluted common share. Non-GAAP net income for the year ago quarter was $8.0 million, or $0.12 per diluted common share.
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of auto-immune diseases.
Crown Equity Holdings Inc. (CRWE)
Advantages of VoIP inlcude: Advance Routing, Extension Mobility, Device Mobility, and Unified Mobility. Multiple routes can be configured, if anyone goes down; voice can be routed to other. If person moves and logs-in to another extension, he/she automatically gets pre-configured settings e.g. Email. If person moves with laptop / softphone /ip device; and plugs-in his/her IP device wherever moves (within IP Network) will automatically get saved configurations. If a person is not on desk, voice calls can be forwarded to multiple extensions with preferences. If 1st preference (extension) is unattended call will be routed to second preference and so on
Crown Equity Holdings Inc. (CRWE.OB) (www.crownequityholdings.com) announced that its subsidiary Crown Tele Services Inc. has entered into a letter of intent with BBN Solutions.
BBN Solutions, located in India, and Crown Tele Services Inc. (www.crownteleservices.com) shall form a 50/50 Joint Venture corporation for the purpose of granting to Crown Tele Services Inc., exclusive rights in the United States to BBN's telecommunications marketing process and services.
Commenting on the Letter of Intent, Kenneth Bosket, President of Crown Tele Services Inc., stated: "This Joint Venture will give both companies a strategic advantage within the communication market.
Crown Tele Services Inc. is a provider of affordable, world class (VoIP) communications solutions and is a subsidiary of Crown Equity Holdings Inc. For more information visit www.crownteleservices.com
Crown Equity Holdings Inc. offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
BBN Solutions doing business as BBN Telecom provides both wholesale and retail global communication, as well as calling cards. For more information visit www.bbntel.net
For more information about Crown Equity Holdings Inc., please visit: www.crownequityholdings.com
Heska Corporation (NASDAQ:HSKA), reported financial results for its fourth quarter and full year ended December 31, 2011. Fourth quarter 2011 revenue was $15.5 million as compared to $15.0 million in the fourth quarter of 2010. In the fourth quarter of 2011, Core Companion Animal Health revenue grew approximately 6.4% to $12.8 million from $12.0 million in the prior year period and Other Vaccines, Pharmaceuticals and Products revenue decreased approximately 9.1% to $2.8 million from $3.0 million in the same timeframe. In the third quarter of 2010, the USDA validated an improved process for a line of the company's cattle vaccines, allowing the company to ship a significant quantity of product in a category which had previously been on hold due to regulatory concerns. Gross profit was $6.6 million, or a 42.5% gross margin, in the fourth quarter of 2011 compared with gross profit of $6.1 million, or 40.9% gross margin, in the fourth quarter of 2010. Total operating expenses were $6.2 million, or 39.9% of sales, in the fourth quarter of 2011 compared with total operating expenses of $5.5 million, or 36.4% of sales, in the prior year period. The Company reported operating income of $414 thousand in the fourth quarter of 2011, compared to operating income of $688 thousand in the fourth quarter of 2010.
Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for canine and feline companion animal health markets in the United States and internationally.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that the Company will be presenting at the following upcoming investor conferences: Citi 2012 Global Healthcare Conference in New York. Monday, February 27 at 10:00 a.m. (ET). RBC Capital Markets' 2012 Healthcare Conference in New York. President and CEO Safi Bahcall, Ph.D., will participate in a panel discussion titled: Unique, Later Stage Cancer Treatment Opportunities. Tuesday, February 28 at 11:00 a.m. (ET). A live audio webcast and replay of both the presentation and panel discussion will be available on the "Investors" section of the Company's website, www.syntapharma.com. Synta will also be attending the UBS Securities Small/Mid-Cap Conference in Boston, February 29, 2012. There is no formal presentation during the UBS Conference, however management will be available for one-on-one meetings during the conference.
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.
For FREE Daily Stock Alerts & Updates Sign-up At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.